Johnson & Johnson MedTech, a leader in cardiac arrhythmia treatment, has announced new clinical and real-world data related to its VARIPULSETM Platform for pulsed field ablation (PFA) procedures aimed at treating atrial fibrillation (AF). This information will be shared at the joint annual meeting of the Asia Pacific Heart Rhythm Society (APHRS) and the Japanese Heart Rhythm Society (JHRS), taking place from November 12 to 15, 2025, in Yokohama, Japan.
The fully integrated VARIPULSETM Platform comprises the VARIPULSETM Catheter, TRUPULSETM Generator, and CARTOTM 3 Mapping System, along with VARIPULSETM Software. This platform has received approval for use across several regions, including the United States, Europe, Asia Pacific, Canada, and Latin America. To date, over 25,000 procedures have been conducted globally, encompassing the U.S., Europe, Canada, Japan, Hong Kong, Mainland China, Korea, Taiwan, and Australia.
In a statement, Jing Li, Vice President of Electrophysiology & Neurovascular at Johnson & Johnson, emphasized the company”s commitment to enhancing scientific knowledge and fostering collaborations aimed at improving patient outcomes. “The clinical evidence we”re presenting at this year”s APHRS and JHRS—highlighting our fully integrated-by-design CARTOTM 3 Mapping System and VARIPULSETM Platform for pulsed field ablation—alongside a robust scientific program, immersive tech-suite experience, and forward-looking pipeline discussions, reflects our deep commitment and the comprehensive strength of our leading portfolio for atrial fibrillation and complex arrhythmias,” Li noted.
Key presentations during the event will include:
- QUEST AF: An oral presentation discussing the “Acute success of persistent atrial fibrillation ablation with a temperature-controlled very high-power short-duration radiofrequency catheter: initial real-world experience from QUEST AF.”
- VARIPURE (SECURE): A poster presentation focusing on “Real-world workflow, efficiency, and vein-level analysis for a novel pulsed field ablation variable loop circular catheter in AF procedures: insights from VARIPURE.”
- admIRE: An oral session examining the “Impact of age and diagnosis-to-ablation time on sex differences in 12-month outcomes after catheter ablation for atrial fibrillation,” along with a hot line session discussing “Procedural characteristics and clinical outcomes from same-day discharge after pulsed field ablation treatment for atrial fibrillation: an admIRE trial subanalysis.”
- REAL AF: A poster viewing session addressing “Right-Sided First Pass Isolation: A Critical Marker of Ablation Efficacy in Atrial Fibrillation,” and an oral session on “Bilateral First Pass Isolation as a Key Procedural Endpoint for Successful Atrial Fibrillation.” Additional presentations will cover “An Analysis of the Benefits of Carina Ablation as an Adjunct to Pulmonary Vein Isolation” and a retrospective study on “Sex Differences in Catheter Ablation Outcomes for Atrial Fibrillation.”
Johnson & Johnson MedTech remains committed to collaborating with the clinical community to expand real-world evidence surrounding the VARIPULSETM Platform and to drive patient-centered innovation in the management of atrial fibrillation.
The company is recognized globally for addressing complex health challenges through its cardiovascular portfolio, which includes advanced mapping and navigation technologies, miniaturized devices, and precise ablation solutions to address significant unmet medical needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation.
For more information about Johnson & Johnson MedTech, interested parties can visit their website.
